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Abstract
Background: The opposite effects of chemotherapy, which enhance the malignancy of treated cancers such as 
hepatocellular carcinoma (HCC), are not well understood. We investigated this phenomenon and corresponding 
mechanisms to develop a novel approach for improving chemotherapy efficacy in HCC.
Methods: Human hepatocellular carcinoma cell lines HepG2 (with low metastatic potential) and MHCC97L (with 
moderate metastatic potential) were used for the in vitro study. An orthotopic nude mouse model of human HCC was 
developed using MHCC97L cells. We then assessed the metastatic potential of surviving tumor cells after in vitro and in 
vivo oxaliplatin treatment. The molecular changes in surviving tumor cells were evaluated by western blot, 
immunofluorescence, and immunohistochemistry. The Chinese herbal extract Songyou Yin (composed of five herbs) 
was investigated in vivo to explore its effect on the metastatic potential of oxaliplatin-treated cancer cells.
Results: MHCC97L and HepG2 cells surviving oxaliplatin treatment showed enhanced migration and invasion in vitro. 
Residual HCC after in vivo oxaliplatin treatment demonstrated significantly increased metastasis to the lung (10/12 vs. 
3/12) when re-inoculated into the livers of new recipient nude mice. Molecular changes consistent with epithelial-
mesenchymal transition (EMT) were observed in oxaliplatin-treated tumor tissues and verified by in vitro experiments. 
The Chinese herbal extract Songyou Yin (4.2 and 8.4 g/kg) attenuated EMT and inhibited the enhanced metastatic 
potential of residual HCC in nude mice (6/15 vs. 13/15 and 3/15 vs. 13/15, respectively).
Conclusions: The surviving HCC after oxaliplatin treatment underwent EMT and demonstrated increased metastatic 
potential. Attenuation of EMT by Songyou Yin may improve the efficacy of chemotherapy in HCC.
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies in many countries, including China.
Radical treatment, such as surgical resection and ortho-
topic liver transplantation, is feasible only for patients
with small tumors [1]. For the majority of patients with
unresectable HCC, the response rate of systemic chemo-
therapy with Adriamycin, 5-fluorouracil and platinum-
based combinations was reported to be approximately
20%, and no survival benefit was observed [2].
Biological deterioration after chemotherapy has
recently been reported. An "opposite effect" of chemo-
therapy has been demonstrated in which cyclophosph-
amide pretreatment induced metastasis of fibrosarcoma
cells in a nude mouse model [3]. Other studies also
reported that in vitro exposure to chemotherapeutic
agents enhanced metastatic potential in colorectal, pan-
creatic, breast, and ovarian carcinoma cells [4-7]. Two
explanations have been proposed for this opposite effect.
Chemotherapy may damage the vascular endothelium
and inhibit the host antitumor system, enabling increased
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tumor cell extravasation and survival [3,8]. Alternatively,
chemotherapy may induce epithelial-mesenchymal tran-
sition (EMT) and enhance the metastatic potential of
tumor cells [4-7]. EMT is characterized by the loss of epi-
thelial marker E-cadherin and expression of mesenchy-
mal markers such as N-cadherin and vimentin; it is
regarded as a critical step in tumor invasion and metasta-
sis [9]. Although these studies established a relationship
among in vitro chemotherapy, EMT, and enhanced tumor
metastasis, the altered metastatic potential of residual
cancer after in vivo chemotherapy is not completely
understood.
To exclude the influence of tumor burden, vascular
injury, and inhibition of host antitumor system by che-
motherapy, we designed a re-inoculation experiment in a
nude mouse model of human HCC to determine whether
chemotherapy promotes a more malignant phenotype of
residual HCC. Because platinum-based combined che-
motherapy targets HCC [10,11], oxaliplatin was selected
as the chemotherapeutic agent in this study. We investi-
gated potential mechanisms, as well as the Chinese herbal
extract Songyou Yin as a potential intervention.
Methods
Cell lines
In the present study, we used two human HCC cell lines:
MHCC97L cells, which originated from MHCC97 [12,13]
(established at the Liver Cancer Institute, Zhongshan
Hospital, Fudan University, Shanghai, China), and HepG2
cells (American Type Culture Collection). MHCC97L
cells show a moderate metastatic potential, and HepG2
cells show a low metastatic potential. All cells were cul-
tured with Dulbecco's Modified Eagle Medium (DMEM)
containing 10% fetal bovine serum (FBS) and incubated
in a humidified incubator at 37°C in 5% CO2.
Compounds and antibodies
Oxaliplatin was purchased from Sigma Chemical Co. (St.
Louis, MO, USA). Monoclonal antibodies used in immu-
nofluorescence, immunoblotting, and immunohis-
tochemistry included: rabbit anti-human vimentin, Twist,
and Slug (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), rabbit anti-human E-cadherin and Snail (Abcam
Ltd., Cambridge, UK), mouse anti-human N-cadherin
(Abcam Ltd, Cambridge, UK.), mouse anti-human
GAPDH (Chemicon, CA, USA) and mouse anti-human
Ki-67 (Dako, Glostrup, Denmark).
Treatment of tumor cells with oxaliplatin and analysis of 
cell morphology
MHCC97L or HepG2 cells were plated in six-well tissue
culture plates (1 × 105 cells/well). After 24 h, the medium
was replaced with DMEM containing 10% FBS and 2
μmol/L oxaliplatin. After 48 h, the medium was changed,
and drug treatment was terminated. Cells were allowed to
recover, and when the surviving populations reached 80%
confluence, cells were passaged and exposed to oxalipla-
tin again for 48 h. During 6 weeks of treatment this pro-
cess was repeated for a total of four 48-h exposures to
oxaliplatin. Cells surviving treatment (Oxa cells) were
designated MHCC97L-Oxa and HepG2-Oxa, respec-
tively. The morphological characteristics of parental and
Oxa cells were compared by microscopy (Olympus,
Tokyo, Japan).
Cell migration and invasion assays
Cell migration was assessed by transwell assay (Boyden
chambers) (Corning, Cambridge, MA, UK). Briefly, 6 ×
104 cells in serum-free DMEM were seeded on a mem-
brane (8.0-μm pore size) inserted in a well of a 24-well
plate. DMEM containing 10% FBS was added to the lower
chamber of each well. After 48 h, cells that had reached
the underside of the membrane were stained with Giemsa
(Sigma Chemical Co.) and counted at × 200 magnifica-
tion. The cell invasion assay was carried out similarly,
except that 10 μL of matrigel (BD Biosciences) was added
to each well 6 h before cells were seeded on the mem-
brane.
Cell proliferation assay
MHCC97L and HepG2 parental and Oxa cells were incu-
bated in 96-well plates (5 × 103 cells/well) for 24, 48, or 72
h. Cell proliferation was then determined with an MTT
kit (Beyotime, Shanghai, China). Results were expressed
as the absorbance of each well at 570 nm (OD570).
Western blot analysis and immunofluorescence
The concentration of protein extracted from Oxa and
parental cells was determined with the BCA Protein
Assay Kit (Beyotime, Shanghai, China). The expression of
E-cadherin, N-cadherin, vimentin, Snail, Slug, and Twist
was determined by immunoblotting as previously
described [14].
E-cadherin, N-cadherin, and vimentin expression in
parental and Oxa cells were also demonstrated by immu-
nofluorescence. Cells were grown on glass cover slips to
40%-50% confluence, and then fixed, permeabilized, and
blocked. Cells were then incubated with primary mono-
clonal antibodies against E-cadherin, N-cadherin, and
v i m e n t i n  o v e r n i g h t  a t  4 ° C .  T h e  n e x t  d a y ,  s l i d e s  w e r e
washed and incubated with anti-mouse and/or anti-rab-
bit fluorescein isothiocyanate (FITC)- and/or tetramethyl
rhodamine isothiocyanate (TRITC)-conjugated second-
ary antibody (Invitrogen). Cells were counterstained with
4'-6-diamidino-2-phenylindole (DAPI) to visualize cell
nuclei and visualized by fluorescence microscopy (Olym-
pus, Tokyo, Japan).Xiong et al. BMC Cancer 2010, 10:219
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Animals
Male BALB ⁄ c nu ⁄ nu mice (age, 4-6 weeks old; weight,
approximately 20 g) were obtained from the Shanghai
Institute of Materia Medica (Chinese Academy of Sci-
ence) and maintained under standard pathogen-free con-
ditions. The experimental protocol was approved by the
Shanghai Medical Experimental Animal Care Commis-
sion.
Pilot study for animal model
T o evalua t e changes in metasta tic pot ential of residual
HCC cells after in vivo oxaliplatin treatment, residual
cancer from the livers of oxaliplatin-treated and
untreated nude mice were re-inoculated orthotopically
into new recipient nude mice. Because the treated and
untreated tumors needed to be histologically similar, a
pilot study compared the histology of treated and
untreated tumors at different time points after chemo-
therapy to determine the appropriate time points for re-
inoculation.
A metastatic model of human HCC in nude mice using
MHCC97L cells was employed for this pilot study [12].
Briefly, MHCC97L cells (5 × 106) were injected subcuta-
neously into the upper left flank region of nude mice.
When the subcutaneous tumor reached approximately 1
cm in length (approximately 4 weeks after injection), it
was removed, minced into small pieces of equal volume
(2 × 2 × 2 mm3), and transplanted into the livers of 60 dif-
ferent nude mice. Based on the literature [15] and the
results of our previous studies, a dosage for oxaliplatin of
10 mg/kg, once a week was adopted in the present study.
Oxaliplatin was administered intraperitoneally (i.p.) to
randomly selected mice (oxaliplatin treatment group; n =
30) on days 12, 19, and 26 after inoculation; the control
group (n = 30) received 0.2 mL of 0.9% sodium chloride
(i.p.) on those days. On days 1, 2, 5, 7 and 14 after the final
treatment, six mice from each group were sacrificed by
cervical dislocation. The necrosis and apoptosis of
tumors in each group were compared.
Analysis of tumor necrosis and apoptosis
Paraffin-embedded sections were prepared for hematox-
ylin and eosin staining. Necrosis of tumor tissue was
determined by comparing the surface of necrotic areas to
that of the whole tumor [16]. Apoptosis was determined
using a terminal transferase dUTP nick end labeling
(TUNEL) assay kit (KeyGen, Nanjing, China) according
to the manufacturer's protocol. The apoptosis rate was
expressed as a ratio of apoptotic cells to total tumor cells.
Re-inoculation experiment
Analysis of tumor histology in the pilot study showed that
tumor necrosis and apoptosis on days 5, 7 and 14 after the
final oxaliplatin treatment were not significantly different
between the control group and the treated group. We
therefore used day 7 tumors for re-inoculation. Orthoto-
pic models of human HCC were established in 36 nude
mice and treated with oxaliplatin (n = 18) or sodium chlo-
ride (n = 18) using the same protocol described for the
pilot study. On day 7 after the final treatment, all mice
were sacrificed by cervical dislocation. Tumor fragments
of equal volume (2 × 2 × 2 mm3) from each mouse of the
oxaliplatin-treated and untreated control groups were re-
inoculated into the livers of each new recipient mice cor-
respondently. The remaining tumor tissues of both
groups were fixed in 10% buffered formalin and embed-
ded in paraffin wax for histological study.
These mice, segregated into control (bearing untreated
tumors, n = 18) and trial ( bearing oxaliplatin pre-treated
tumors, n = 18) groups, were then kept under standard
conditions. On day 42 after re-inoculation, 12 randomly
selected mice from each group were sacrificed, and
tumor growth and pulmonary metastasis were assessed.
Tumor tissues from re-inoculated mice were also pre-
pared for histological study. The remaining six mice from
each group were kept for survival analysis.
Characterization of the Chinese herbal extract Songyou Yin
The water-soluble Chinese herbal medicine Songyou Yin
(SYY), authorized by the Chinese State Food and Drug
Administration (Grant No. G20070160), includes five
Chinese medicinal herbal extracts in the following pro-
portions (w/w): Salvia miltiorrhiza Bge., 14.3%; Astrag-
alus membranaceus Bge., 14.3%; Lycium barbarum L.,
23.8%; Crataegus pinnatifida Bge., 23.8% and Trionyx sin-
ensis  Wiegmann, 23.8% (all from China). High-perfor-
mance liquid chromatography (HPLC) fingerprinting of
Songyou Yin and its five characteristic components (see
additional file 1) was carried out by the Shanghai Institute
of Materia Medica (SIMM), Chinese Academy of Sci-
ences (CAS), China [17]. The SYY used in this study was
produced by the Caitong Detang Chinese Traditional
Medicine Pharmaceutical Factory (batch number:
090401; Shanghai, China).
Songyou Yin treatment in the re-inoculation model beaing 
oxaliplatin pre-treated tumors
The orthotopic nude mice model bearing oxaliplatin pre-
treated MHCC97L xenografts was established in 84 mice
using the previously described protocol. Three days after
re-inoculation, mice were randomized into control (n =
21) and SYY-treated groups (n = 63). The 63 nude mice in
the SYY-treated group received SYY at three different
doses (2.1, 4.2, and 8.4 g/kg; each dose, n = 21) by oral
gavage once per day. Mice in the control group received
0.2 mL of 0.9% sodium chloride via oral gavage at theXiong et al. BMC Cancer 2010, 10:219
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same time. Treatment continued for 6 consecutive weeks.
On day 42 after initiation of treatment, mice from the
control group and each SYY dose group (each group, n =
15) were sacrificed to determine tumor volume. The
tumor tissue and lungs were collected for histological
analysis and a pulmonary metastasis assay. The remain-
ing mice were maintained and used for survival analysis.
Tumor volume, lung metastasis and survival
Tumor volume was calculated as: (a × b2)/2, where "a" is
the widest diameter and "b" is the smallest [18]. Lung
metastasis was determined by examining serial sections
of every lung tissue block by microscopy. Survival time
was defined as the interval between the day of inocula-
tion and the day of death.
Immunohistochemistry
Tumor tissue was fixed, embedded, and sliced into 5-μm
thick sections. Immunostaining of E-cadherin, N-cad-
herin, vimentin, Snail, Slug, and Twist was carried out
using a standard protocol [19].
Statistical analysis
In vitro cell migration, invasion, and proliferation assays
were analyzed by Student's t-test. Necrosis and apoptosis
of tumors from the animal model were also compared by
Student's t-test. Tumor volume was compared by analysis
of variance (ANOVA), the lung metastasis assay was ana-
lyzed using Fisher's exact test, and survival was compared
with Kaplan-Meier method with a log-rank test. Statisti-
cal analysis was performed with SPSS 15.0 for Windows
(SPSS Inc. Chicago, IL, USA). P < 0.05 was considered
statistically significant.
Results
Tumor cells that survived oxaliplatin treatment showed 
higher motility and invasiveness and slower proliferation in 
vitro
In the migration assay (Figure 1), cells that survived oxali-
platin treatment migrated through the membrane in
greater numbers compared with corresponding parental
cells (MHCC97L-Oxa, 29.50 ± 5.28 vs. MHCC97L, 19.17
± 2.64; P=0.002; and HepG2-Oxa, 21.17 ± 3.13 vs.
HepG2, 12.33 ± 2.73; P < 0.001). In the invasion assay
(Figure 2), MHCC97L-Oxa and HepG2-Oxa cells showed
a 0.89-fold(P < 0.001) and 1.58-fold (P =0.001) increase,
respectively, in the number of cells invading the matrigel-
coated membrane, compared with untreated controls. At
48 and 72 h after plating, both MHCC97L-Oxa and
HepG2-Oxa cells exhibited reduced proliferation com-
pared with corresponding parental cells (Figure 3B).
Tumor cells surviving oxaliplatin treatment exhibited EMT 
in vitro
MHCC97L-Oxa and HepG2-Oxa cells were morphologi-
cally distinct from the typical epithelial appearance of
parental MHCC97L and HepG2 cells, demonstrating a
spindle shape with less cell-cell adhesion and increased
formation of pseudopodia (Figure 3A). Western blot anal-
ysis (Figure 3C) showed a significant reduction in E-cad-
herin expression with an upregulation of N-cadherin and
vimentin in MHCC97L-Oxa and HepG2-Oxa cells. The
transition from a dominant E-cadherin distribution in the
cell membrane before chemotherapy to predominant N-
cadherin expression after chemotherapy, known as the
"cadherin switch" [20], was also demonstrated by immun-
ofluorescence in both cell lines (Figure 3D). Furthermore,
an upregulation of the transcription factor Snail was also
Figure 1 Tumor cells that survived oxaliplatin treatment showed 
enhanced migration in vitro. The transwell assay demonstrated that 
MHCC97L-Oxa and HepG2-Oxa cells migrated through the collagen 
membrane in greater numbers compared with parental MHCC97L and 
HepG2 cells.Xiong et al. BMC Cancer 2010, 10:219
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detected in MHCC97L-Oxa and HepG2-Oxa cells (Fig-
ure 3C). However, expression of the transcription factors
Twist and Slug was very low and was not affected by
oxaliplatin treatment in either cell line (data not shown).
Oxaliplatin treatment resulted in transient histological 
changes in tumor tissues primarily via apoptosis induction
To explore the feasibility of re-inoculation, the histology
of tumor tissues between the control and oxaliplatin
treatment group was compared at various time points. As
shown in Figure 4A, no significant difference in tumor
necrosis was observed between the control group and
oxaliplatin treatment group. Tumors in the control group
maintained a basal apoptosis rate of approximately 3%
throughout the 2-week experiment; however, oxaliplatin-
treated tumors demonstrated significantly increased
apoptosis on day 2 after the final oxaliplatin injection
(Figure 4B, C). No significant difference in apoptosis was
observed between the two groups at other time points.
Residual tumors after oxaliplatin treatment exhibited 
enhanced metastatic potential in re-inoculated nude mice
To evaluate biological features of HCC tumors after che-
motherapy, MHCC97L xenografts from the oxaliplatin-
treated and untreated control groups were re-inoculated
into the livers of new recipient mice. Six weeks after re-
inoculation, tumor volumes in the trial (bearing oxalipla-
tin pre-treated tumors) and control (bearing untreated
tumors) groups were 2624.59 ± 491.60 and 3849.72 ±
827.09 mm3 (P < 0.001) respectively. In addition, Ki-67
positive cells were significantly reduced in oxaliplatin
pre-treated tumors (see additional file 2).
Analysis of serial lung sections revealed that oxaliplatin
pre-treated tumors gave rise to spontaneous pulmonary
metastasis in 83% (10/12) of the mice in the trial group
(see additional file 3). In contrast, pulmonary metastasis
was found in only 25% (3/12) of the mice in the control
group (P = 0.012).
However, no significant difference was found between
the trial group and control group in mean survival time
(55.17 ± 5.53 vs. 51.33 ± 4.63 days; P = 0.128).
Residual tumors after chemotherapy exhibited changes 
consistent with EMT in nude mice
On day 7 after chemotherapy, oxaliplatin-treated and
untreated tumors were subjected to immunohistochem-
istry (Figure 5). Untreated tumors showed typical mem-
branous E-cadherin expression in the cell-cell contacts.
In contrast, oxaliplatin-treated tumors showed an overall
reduction of E-cadherin expression, especially at the
invasive front where the expression of E-cadherin was
faint or even undetectable. The mesenchymal marker N-
cadherin was significantly upregulated in oxaliplatin-
treated tumors. N-cadherin-positive tumor cells were
concentrated primarily in areas of tumor-stroma interac-
tion and were scattered in the stroma. Increased cyto-
plasmic expression of vimentin, another mesenchymal
marker, was also detected in oxaliplatin-treated tumors.
We also analyzed the expression of transcription factors
Snail, Slug, and Twist in tumor tissues. However, only
Snail was detected; it was significantly upregulated in
oxaliplatin-treated tumors.
A comparison was also carried out between the control
group (re-inoculated with untreated tumor) and trial
group (re-inoculated with oxaliplatin pre-treated tumor),
producing similar results. A much more frequent and
active EMT was observed in tumors of the trial group
than the control group (see additional file 4).
Songyou Yin inhibited metastasis of oxaliplatin pre-treated 
tumors and increased survival
After 6 weeks, 8.4 g/kg SYY treatment resulted in
decreased tumor volume compared with the control
group (1969.95 ± 454.32 mm3 vs. 2841.87 ± 417.59 mm3;
Figure 2 Tumor cells that survived oxaliplatin treatment exhibit-
ed enhanced invasive properties in vitro. MHCC97L-Oxa and 
HepG2-Oxa cells showed significant increase in the numbers of cells 
invading the Matrigel-coated membrane compared with parental 
MHCC97L and HepG2 cells in the modified transwell assay.Xiong et al. BMC Cancer 2010, 10:219
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P < 0.001). With this SYY dose, maximum inhibition of
pulmonary metastasis (3/15 vs. 13/15; P = 0.001) and pro-
longed survival was also observed (81.17 ± 7.36 days vs.
53.83 ± 4.71 days; P = 0.001) (Figure 6A-C). In contrast,
2.1 g/kg SYY treatment did not significantly reduce
tumor volume, incidence of pulmonary metastasis, or
mean survival time. Although 4.2 g/kg SYY did not signif-
icantly inhibit tumor growth (2470.41 ± 583.96 mm3 vs.
2,841.87 ± 417.59 mm3; P = 0.065), this dose decreased
the incidence of pulmonary metastasis (6/15 vs. 13/15; P
= 0.021) and increased life span (66.67 ± 5.61 days vs.
53.83 ± 4.71 days; P = 0.002).
To explore the relationship between SYY treatment and
EMT, tumor tissues in SYY-treated nude mice and con-
trol mice were analyzed by immunohistochemistry. Com-
pared with the control, EMT was less common in tumors
from mice treated with 8.4 g/kg or 4.2 g/kg SYY. A resto-
ration of E-cadherin expression (Figure 6D) and a con-
comitant reduction in N-cadherin expression (Figure 6E)
were detected in these tumors. The expression of vimen-
tin was low or even undetectable in most tumors in these
two SYY treatment groups.
Discussion
Chemoresistance and chemotherapy side effects in HCC
treatment have been studied; however, little is known
about the opposite effect of chemotherapy. Consistent
with the studies on other malignant tumors [4-7], we
showed that in vitro exposure of MHCC97L and HepG2
HCC cells to pulse treatment with oxaliplatin led to
Figure 3 Exposure to oxaliplatin in vitro induced epithelial-mesenchymal transition (EMT) in MHCC97L and HepG2 cells. A) Tumor cells sur-
viving oxaliplatin treatment were morphologically distinct from the typical epithelial appearance of parental MHCC97L and HepG2 cells, demonstrat-
ing a spindle shape with less cell-cell adhesion and increased formation of pseudopodia. B) MTT assay revealed a reduced proliferation in MHCC97L-
Oxa and HepG2-Oxa cells compared with the respective parental cells. C) Western blot analysis showed molecular changes consistent with EMT in 
MHCC97L-Oxa and HepG2-Oxa cells (e.g., downregulation of E-cadherin and upregulation of N-cadherin, vimentin, and transcription factor Snail). 
GAPDH was used as an internal control. D) Reduced E-cadherin expression and increased expression of N-cadherin, and vimentin in MHCC97L-Oxa 
and HepG2-Oxa cells were also demonstrated by immunofluorescence.Xiong et al. BMC Cancer 2010, 10:219
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increased motility and invasiveness of the surviving
tumor cells. However, in vivo study is more complicated;
chemotherapy affects not only tumor cells but also dam-
ages blood vessels and inhibits the antitumor system of
the host, which may contribute to cancer metastasis [3,8].
Furthermore, chemotherapy directly influences tumor
burden, and tumor burden strongly correlates with the
incidence of pulmonary metastasis (i.e., metastasis occurs
more frequently with larger tumors). To avoid these con-
founding factors, we employed a re-inoculation model.
The similarity in histology between the untreated tumors
and oxaliplatin-treated tumors on day 7 after chemother-
apy support the validity of this model. Finally, oxaliplatin
pre-treated tumors showed a 2.3-fold increase in the inci-
dence of spontaneous metastasis to the lungs of the new
recipient mice. These results indicated that HCC cells
surviving in vitro and in vivo oxaliplatin treatment have
increased metastatic potential, a possible opposite effect
of oxaliplatin treatment.
Accumulating evidence indicates that EMT plays an
important role in chemotherapy-induced invasiveness in
colorectal, pancreatic, breast and ovarian carcinoma cells
in vitro. We showed here that pulse exposure to oxalipla-
tin stimulated transformation of HepG2 and MHCC97L
Figure 4 Analysis of tumor histology after oxaliplatin treatment. A) No significant difference in tumor necrosis was observed between the control 
group and oxaliplatin treatment group after treatment. B) Terminal transferase dUTP nick end labeling (TUNEL) analysis showed a basal level of apop-
tosis rate of about 3% in tumors of the control group throughout the 2-week experiment. In the oxaliplatin treatment group, significant apoptosis was 
observed on day 2 after the final injection (B, C). No significant difference in apoptosis was found between the two groups at other time points.Xiong et al. BMC Cancer 2010, 10:219
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HCC cells from a typical epithelial phenotype to a spin-
dle-shaped mesenchymal phenotype, accompanied by the
loss of E-cadherin and upregulation of N-cadherin and
vimentin. Further evidence was provided by xenografts in
nude mice; molecular alterations consistent with EMT
were detected in tumors on day 7 after chemotherapy.
These observations were consistent with a recent clinical
investigation of breast cancer [21], which indicated that
residual breast cancers after chemotherapy and endo-
crine therapy displayed mesenchymal features. We also
detected upregulated transcription factor Snail in oxalipl-
a t i n - t r e a t e d  t u m o r  t i s s u e s  a n d  c e l l  l i n e s .  T h i s  f i n d i n g ,
combined with results of a previous study using oxalipla-
tin [4], suggests that the Snail signal transduction path-
way may play a central role in oxaliplatin-induced tumor
progression. Finally, the decreased proliferation of oxalip-
latin-treated tumor cells suggests that these tumor cells
may have switched from a proliferative to a more invasive
and migratory phenotype, thus providing further evi-
dence of EMT following chemotherapy [22].
Interestingly, similar changes were also detected in re-
inoculated tumors 6 weeks after re-inoculation. Com-
pared with controls, oxaliplatin pre-treated tumors
showed decreased growth and significantly increased
EMT. This observation indicates that tumor cells surviv-
ing in vivo chemotherapy acquired intrinsic characteris-
tics that facilitated EMT. A possible explanation for this
might be derived from the survival mechanisms of tumor
cells. Molecules such as interleukin (IL)-8 and integrins
not only help tumor cells survive chemotherapy but stim-
ulate EMT [6,23]. These factors may be pre-existing in
minor subpopulations of tumor cells and then selected by
chemotherapy, or they could be induced by chemother-
a p y ,  o r  b o t h  m e c h a n i s m s  m a y  o c c u r .  T h e s e  r e s u l t s ,
together with enhanced pulmonary metastasis rates in re-
inoculated mice, highlight the close relationship among
oxaliplatin treatment, EMT, and metastasis. Further
investigations are needed to characterize the underlying
mechanisms in more detail.
It is not clear whether the increased metastatic poten-
tial of residual HCC after oxaliplatin treatment over-
weighs or is less important to the host than the reduced
tumor burden by chemotherapy; however, the opposite
effect of chemotherapy attenuates its anti-tumor effect as
far as host life span is concerned. As mentioned above,
previous clinical trials failed to show a correlation
between the HCC patients' response to chemotherapy
and prolonged survival. The findings of the present study
suggest that the increased metastatic potential within
residual HCC cells after chemotherapy may be partly
responsible for these results. Indeed, most cancer deaths
are due to metastasis in clinical trials [24]. While much
attention has been paid to reducing tumor burden, the
complex mechanisms involved in chemotherapy-related
tumor progression require clarification, which may even-
tually lead to mechanism-based combination treatments
to improve the efficacy of chemotherapy in HCC.
SYY is a Chinese herbal extract consisting of Salvia
miltiorrhiza  B g e .  a n d  f o u r  o t h e r  h e r b s .  S o m e  c o m p o -
nents of SYY have demonstrated value in treating malig-
nancies [25,26]. In our previous study [17], SYY
effectively inhibited tumor growth and metastasis, and
increased survival in a similar HCC nude mouse model
bearing MHCC97H (a cell line with high metastatic
Figure 5 Oxaliplatin-treated tumors exhibited changes consistent with epithelial-mesenchymal transition (EMT). Immunohistochemistry re-
vealed typical membranous E-cadherin expression in the cell-cell contacts of untreated tumors. In contrast, oxaliplatin-treated tumors showed an 
overall reduction of E-cadherin expression, especially at the invasive front where the expression of E-cadherin was faint or even undetectable. Instead, 
N-cadherin was significantly upregulated in oxaliplatin-treated tumors. N-cadherin-positive tumor cells were concentrated in areas of tumor-stroma 
interaction and were scattered in the stroma. Increased expression of vimentin and Snail were also detected in the invasive front of oxaliplatin-treated 
tumors.Xiong et al. BMC Cancer 2010, 10:219
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potential originating from MHCC97 cells [13]) xenograft.
The induction of apoptosis and downregulation of MMP-
2 and VEGF were suggested to be responsible for the
anticancer effect of SYY. In the present study, we further
evaluated the effects of SYY on oxaliplatin pre-treated
tumors to determine its effects against chemotherapy-
related cancer metastasis. We demonstrated that SYY
treatment at doses of 4.2 g/kg and 8.4 g/kg significantly
inhibited the metastatic potential of residual HCC after
chemotherapy and prolonged mouse survival. Thus SYY
Figure 6 The effect of Songyou Yin on oxaliplatin pre-treated tumors in nude mice. Tumor volume was significantly decreased in mice treated 
with 8.4 g/kg Songyou Yin compared with the control group (A). Songyou Yin treatment (4.2 and 8.4 g/kg) significantly decreased pulmonary metas-
tasis (B) and prolonged survival (C) of nude mice bearing oxaliplatin pre-treated MHCC97L xenografts. Songyou Yin treatment (4.2 g/kg) restored E-
cadherin expression (D) and arrested the cadherin switch (E) in tumor tissues.Xiong et al. BMC Cancer 2010, 10:219
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treatment may attenuate the opposite effect of oxaliplatin
treatment, thereby improving treatment efficacy. Fur-
thermore, the restoration of E-cadherin and arrest of cad-
herin switch in SYY-treated tumors suggest that EMT
inhibition may play a role in SYY effects. In addition to
recent studies that demonstrated EMT attenuation by a
herbal prescription Wen-pi-tang-Hab-Wu-ling-san and a
medicinal herb Panax notoginseng in kidney cells against
fibrosis[27,28], we showed here that the arrest of EMT
was also linked to the anticancer effects of traditional
Chinese medicine. Expression of MMP2 and VEGF was
found to be important in the EMT program, with rele-
vance to the induction of transcription factor Snail
[21,23,29]. Hence, the attenuation of EMT by SYY dem-
onstrated in the present study supports our previous
findings by providing underlying mechanisms. One limi-
tation of the present study is the lack of detailed under-
standing of the relationship between EMT arrest and SYY
treatment due to its complexity. Therefore, additional
basic research is needed.
Conclusions
Our results suggest that residual HCC cells after oxalipla-
tin treatment undergo EMT and exhibit increased meta-
static potential. Accordingly, attenuation of EMT by SYY
may improve the efficacy of chemotherapy in HCC.
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